Cresset Asset Management, LLC Arcus Biosciences, Inc. Transaction History

Cresset Asset Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$14.83 - $20.18 $9,402 - $12,794	634 Added 1.85%	34,848 $657,000
Q4 2023 Feb 14, 2024	SELL	$13.43 - $19.63 $1,154 - $1,688	-86 Reduced 0.25%	34,214 $653,000
Q3 2023 Nov 14, 2023	SELL	$17.62 - $23.54 $14,677 - $19,608	-833 Reduced 2.37%	34,300 $615,000
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $596,207 - $773,979	35,133 New	35,133 $713,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.01B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Cresset Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Cresset Asset Management, LLC with notifications on news.